Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis
- 주제(키워드) Multiple myeloma , conditioning regimen , autologous stem cell transplantation
- 주제(기타) Oncology
- 주제(기타) Hematology
- 설명문(일반) [Song, Ga-Young; Jung, Sung-Hoon; Lee, Je-Jung] Chonnam Natl Univ, Dept Hematol Oncol, Hwasun Hosp, 322 Seoyangro, Hwasun 519763, South Korea; [Kim, Jin Seok] Yonsei Univ, Severance Hosp, Dept Internal Med, Div Hematol,Coll Med, 50-1 Yonsei Ro, Seoul 03722, South Korea; [Min, Chang-Ki] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea; [Kim, Kihyun] Samsung Med Ctr, Seoul, South Korea; [Choi, Yunsuk] Ulsan Univ Hosp, Ulsan, South Korea; [Eom, Hyeon-Seok] Natl Canc Ctr, Goyang Si, South Korea; [Joo, Young Don] Inje Univ, Busan Paik Hosp, Busan, South Korea; [Kim, Sung-Hyun] Dong A Med Ctr, Busan, South Korea; [Kwak, Jae-Yong] Chonbuk Natl Univ, Med Sch, Jeonju, South Korea; [Kang, Hye Jin] Korea Canc Ctr Hosp, Korea Inst Radiol & Med Sci, Seoul, South Korea; [Lee, Jae Hoon] Gachon Univ, Gil Hosp, Incheon, South Korea; [Lee, Ho Sup] Kosin Univ, Gospel Hosp, Busan, South Korea; [Mun, Yeung-Chul] Ewha Womans Univ, Sch Med, Seoul, South Korea; [Moon, Joon Ho; Sohn, Sang Kyun] Kyungpook Natl Univ Hosp, Daegu, South Korea; [Park, Seong Kyu] Soonchunhyang Univ, Bucheon Hosp, Bucheon, South Korea; [Park, Yong] Korea Univ, Coll Med, Seoul, South Korea; [Shin, Ho-Jin] Pusan Natl Univ Hosp, Busan, South Korea; [Yoon, Sung-Soo] Seoul Natl Univ Hosp, Seoul, South Korea
- 등재 SCIE, SCOPUS
- 발행기관 TAYLOR & FRANCIS LTD
- 발행년도 2020
- 총서유형 Journal
- URI http://www.dcollection.net/handler/ewha/000000174989
- 본문언어 영어
- Published As http://dx.doi.org/10.1080/10428194.2020.1783448
- PubMed https://pubmed.ncbi.nlm.nih.gov/32580672
초록/요약
We compared the efficacy and toxicity of busulfan and melphalan (BUMEL) and those of high-dose melphalan (HDMEL) as conditioning regimens for autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM) through a propensity score-matched analysis. No significant difference in the complete response and overall response rate after ASCT was observed between BUMEL and HDMEL. After a median follow-up of 37.3 months in the BUMEL group and 50.8 months in the HDMEL group, the median progression-free survival was calculated to be 32.9 months and 25.2 months (p = 0.995). With respect to non-hematologic toxicities, infections were more frequently reported in the BUMEL group (p < 0.001). Three patients who received BUMEL developed veno-occlusive disease (VOD), and all of them recovered without administration of defibrotide. In conclusion, BUMEL is an effective alternative conditioning regimen in terms of efficacy, but attention should be paid to toxicities.
more